We have a comprehensive intellectual property portfolio for treatment of solid tumors to improve patient outcomes.
We have completed a first in human trial using our antibody, called Miltuximab®.
We have completed a first in human trial using our antibody, called Miltuximab
developing solid tumors therapeutics.
Miltuximab® for Therapeutic & Imaging Applications.
- Radio immunotherapy
- Bispecific antibodies
- Immune cell engagement and activation
First-In-Human Clinical trial of Miltuximab® conjugated to 67Gallium for imaging met primary endpoint of safety in all patients
Preclinical work now completed for upcoming Phase I Clinical trial in GPC-1 expressing solid tumours. This will use Miltuximab® labelled with either 89Zirconium for imaging or 177Lutetium for therapy
Antibody composition of matter patents granted EU and US
Completion of accrual for clinical study of Miltuximab® in prostate, bladder and pancreatic cancers
The second stage of pioneering MILGa clinical trial of Miltuximab®
Commenced First-In-Human trial of Miltuximab®